We have re-examined whether pp60(c-src), the normal cellular homologue of the transforming protein of Rous sarcoma virus, is present in human T cells. By in vitro immune-complex kinase assay or Western blotting with the anti- pp60(c-src) mAbs 327 or GD11, pp60(c-src) was found to be present in lysates of T cell lines, including the Jurkat T cell line. The 327 and GD11 mAbs have been reported to be specific for pp60(c-src) and not to cross-react with other src family members or other kinases. Furthermore, the size of the pp60(c-src) bands present on Western blotting and in vitro kinase assay were clearly different from those of p56(lck) or p59(fyn). In addition, pp60(c- src) is detected in the HTLV-I-derived T cell lines S1T and C8, which lack expression of p56(lck) and p59(fyn). RNase protection assays confirmed that pp60(c-src) mRNA is present in Jurkat T cells. We also found pp60(c-src) protein to be constitutively present in freshly isolated thymocytes. In contrast, pp60(c-src) was absent, or present at extremely low levels, in normal, resting peripheral blood T lymphocytes, which is in agreement with previous findings. However, after stimulation of resting T cells with the mitogenic lectin PHA or with Ab to the TCR complex, pp60(c-src) expression is induced in both CD4+ and CD8+ T cell subsets, with peak expression detectable 12 to 24 h after T cell activation. The levels of pp60(c-src) are low in all T cells except Jurkat, where levels of pp60(c-src) are comparable to levels found in a glioblastoma cell line (T98G). Nevertheless, significant levels of pp60(c-src) kinase activity are readily detectable in thymocytes and activated normal T cells as well as in T cell lines. The finding that pp60(c-src) is inducible following activation through the TCR suggests that pp60(c-src) may play a specific role in the normal T cell activation pathway.
|Original language||English (US)|
|Number of pages||8|
|Journal||Journal of Immunology|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas
- Immunology and Allergy